Cisplatin is an effective drug for treating various cancer types. However, it is highly toxic for both healthy and tumor cells. Therefore, there is a need to reduce its therapeutic dose and increase targeted bioavailability. One of the ways to achieve this could be the coating of cisplatin with polysaccharides and specific carriers for targeted delivery. Nucleic acid aptamers could be used as carriers for the specific delivery of medicine to cancer cells. Cisplatin-arabinogalactan-aptamer (Cis-AG-Ap) conjugate was synthesized based on Cis-dichlorodiammineplatinum, Siberian larch arabinogalactan, and aptamer AS-42 specific to heat-shock proteins (HSP) 71 kDa (Hspa8) and HSP 90-beta (Hsp90ab1). The antitumor effect was estimated using ascites and metastatic Ehrlich tumor models. Cis-AG-Ap toxicity was assessed by blood biochemistry on healthy mice. Here, we demonstrated enhanced anticancer activity of Cis-AG-Ap and its specific accumulation in tumor foci. It was shown that targeted delivery allowed a 15-fold reduction in the therapeutic dose of cisplatin and its toxicity. Cis-AG-Ap sufficiently suppressed the growth of Ehrlich's ascites carcinoma, the mass and extent of tumor metastasis in vivo. Arabinogalactan and the aptamers promoted cisplatin efficiency by enhancing its bioavailability. The described strategy could be very promising for targeted anticancer therapy.
Get full access to this article
View all access options for this article.
References
1.
CasiniA and ReedijkJ. (2012). Interactions of anticancer PT compounds with proteins: an overlooked topic in medicinal inorganic chemistry? Chem Sci, 3:3135–3144.
2.
ReedijkJ. (2011). Increased understanding of platinum anticancer chemistry. Pure Appl Chem, 83:1709–1719.
3.
KellandL. (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 7:573–584.
4.
WangD and LippardSJ. (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov, 4:307–320.
5.
DasariS and TchounwouPB. (2014). Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol, 740:364–378.
6.
ZajdaJ, WróblewskaA, RuzikL and MatczukM. (2021). Methodology for characterization of platinum-based drug's targeted delivery nanosystems. J Control Release, 335:178–190.
7.
RabikCA and DolanME. (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 33:9–23.
8.
MilosavljevicN, DurantonC, DjerbiN, PuechPH, GounonP, Lagadic-GossmannD, Dimanche-BoitrelMT, RauchC, TaucM, et al. (2010). Nongenomic effects of cisplatin: acute inhibition of mechanosensitive transporters and channels without actin remodeling. Cancer Res, 70:7514–7522.
IshidaS, LeeJ, ThieleDJ and HerskowitzI. (2002). Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A, 99:14298–14302.
11.
DharS, GuFX, LangerR, FarokhzadOC and LippardSJ. (2008). Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A, 105:17356–17361.
12.
DharS, KolishettiN, LippardSJ and FarokhzadOC. (2011). Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A, 108:1850–1855.
13.
AgnelloL, TortorellaS, d'ArgenioA, CarboneC, CamoraniS, LocatelliE, AulettaL, SorrentinoD, FedeleM, et al. (2021). Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors. J Exp Clin Cancer Res, 40:239.
14.
ShiraishiK and YokoyamaM. (2019). Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review. Sci Technol Adv Mater, 20:324–336.
15.
DionC, ChappuisE and Ripoll.C (2016). Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials. Nutr Metab (Lond), 13:28.
16.
Kelly GS. (1999). Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide. Altern Med Rev, 4:96–103.
17.
PinhassiRI, AssarafYG, FarberS, StarkM, IckowiczD, DroriS, DombAJ and LivneyYD. (2010). Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules, 11:294–303.
18.
StarkovAK, ZamayTN, SavchenkoAA, IngevatkinEV, TitovaNM, KolovskayaOS, LuzanNA, SilkinPP and KuznetsovaSA. (2016). Antitumor effect of arabinogalactan and platinum complex. Dokl Biochem Biophys, 467:92–94.
19.
ZamayTN, StarkovAK, KolovskayaOS, KichkailoAS, InzhevatkinEV, ZamayGS, TitovaNM, ZamaySS and PatcYuS. (2020). Reduction of the cisplatin toxicity by its conjugation with arabinogalactan. Biochem Moscow Suppl Ser A, 14:61–66.
20.
KolovskayaOS, ZamayTN, ZamayAS, GlazyrinYE, SpivakEA, ZubkovaOA, KadkinaAV, ErkaevEN, ZamayGS, et al. (2014). DNA-aptamer/protein interaction as a cause of apoptosis and arrest of proliferation in Ehrlich ascites adenocarcinoma cells. Biochem Moscow Suppl Ser A, 8:60–72.
21.
StarkovAK, PavlenkoNI and Kozhukhovskaja.GA (2019). Method of obtaining drug based on Cis-diamine(cyclobutane-1,1-dicarboxylateo,o’)platinum(ii) interaction with arabinogalactan. RU2679136C1.
ZamayTN, KolovskayaOS, GlazyrinYE, ZamayGS, KuznetsovaSA, SpivakEA, WehbeM, SavitskayaAG, ZubkovaOA, et al. (2014). DNA-aptamer targeting vimentin for tumor therapy in vivo. Nucleic Acid Ther, 24:160–170.
27.
MaY, ChenH, SuS, WangT, ZhangC, FidaG, CuiS, ZhaoJ and GuY. (2015). Galactose as broad ligand for multiple tumor imaging and therapy. J Cancer, 6:658–670.
28.
GaborF, BognerE, WeissenboeckA and WirthM. (2004). The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev, 56:459–480.
29.
HuJ, LiuJ, YangD, LuM and YinJ. (2014). Physiological roles of asialoglycoprotein receptors (ASGPRs) variants and recent advances in hepatic-targeted delivery of therapeutic molecules via ASGPRs. Protein Pept Lett, 21:1025–1030.
30.
ValladeauJ, Duvert-FrancesV, PinJJ, KleijmeerMJ, Ait-YahiaS, RavelO, VincentC, VegaF, HelmsA, et al. (2001). Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptor-mediated endocytosis. J Immunol, 167:5767–5774.
31.
LiangJX, ZhongHJ, YangG, VellaisamyK, MaDL and LeungCH. (2017). Recent development of transition metal complexes with in vivo antitumor activity. J Inorg Biochem, 177:276–286.
32.
MakIW, EvaniewN and GhertM. (2014). Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res, 6:114–118.
33.
RuggeriBA, CampF and MiknyoczkiS. (2014). Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol, 87:150–161.
34.
Bruijnincx PCA and SadlerPJ. (2009). Controlling platinum, ruthenium and osmium reactivity for anticancer drug design. Adv Inorg Chem, 61:1–62.
35.
FuertesMA, AlonsoC and PérezJM. (2003). Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev, 103:645–662.
36.
JeffersJR, ParganasE, LeeY, YangC, WangJ, BrennanJ, MacLeanKH, HanJ, ChittendenT, et al. (2003). Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell, 4:321–328.
37.
SalvesenGS and DixitVM. (1997). Caspases: intracellular signaling by proteolysis. Cell, 91:443–446.
38.
LinY, MaW and BenchimolS. (2000). PIDD, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet, 26:122–127.
39.
Sharaf el deinO, GallerneC, BrennerC and LemaireC. (2012). Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents. Biochem Pharmacol, 83:1172–1182.
40.
SaadSY, NajjarTAO and AlashariM. (2004). Role of non-selective adenosine receptor blockade and phosphodiesterase inhibition in cisplatin-induced nephrogonadal toxicity in rats. Clin Exp Pharmacol Physiol, 31:862–867.
41.
KohnoK, WangKY, TakahashiM, KuritaT, YoshidaY, HirakawaM, HaradaY, KumaA, IzumiH and MatsumotoS. (2015). Mitochondrial transcription factor A and mitochondrial genome as molecular targets for cisplatin-based cancer chemotherapy. Int J Mol Sci, 16:19836–19850.
42.
JamiesonER and LippardSJ. (1999). Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev, 99:2467–2498.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
